Short Interest in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Increases By 28.6%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 648,700 shares, a growth of 28.6% from the July 31st total of 504,300 shares. Based on an average daily trading volume, of 283,100 shares, the short-interest ratio is currently 2.3 days. Approximately 3.4% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Fundamental Research set a $4.20 price objective on shares of Tevogen Bio and gave the company a “buy” rating in a research report on Friday, June 28th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tevogen Bio stock. Portland Global Advisors LLC purchased a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio accounts for 3.0% of Portland Global Advisors LLC’s holdings, making the stock its 9th largest position. Portland Global Advisors LLC owned approximately 36.55% of Tevogen Bio as of its most recent SEC filing.

Tevogen Bio Price Performance

TVGN opened at $0.52 on Friday. The business’s 50-day moving average price is $0.66. Tevogen Bio has a fifty-two week low of $0.42 and a fifty-two week high of $21.09.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.